Connecting Raw, Processed, and Ancillary Data with a Biomarker Data Management Solution

Connecting Raw, Processed, and Ancillary Data with a Biomarker Data Management Solution

Translational and clinical teams spend more than 70% of their time managing, cleaning, and harmonizing data generated in biomarker-rich clinical programs. In a recent webinar, Adam Brown demonstrated how the QuartzBio® enterprise Biomarker Data Management (eBDM) solution addresses one set of frequently intractable challenges: connecting raw, processed, and ancillary data across multiple clinical studies. Read More →
BDM 14SEP Landing page archive image

Webinar: Overcoming Biomarker Data Chaos with a Single Data Platform

Duration: 30 minutes

Register for the Webinar:

Translational and clinical research teams spend more than 70% of their time wrangling information from disconnected clinical trial data sets.

Data ends up in silos, making it hard to compile information and surface insights.

Watch this short webinar, where Adam Brown and Mike Waters will demonstrate how integrating exploratory biomarker, PK, and clinical data in a unified data platform enables teams to interrogate trends and identify insights as data is generated on-study. 

Read More →
Bioinformatics Strategy Meeting QuartzBio 2022

May 23: Join QuartzBio at the Bioinformatics Strategy Meeting East Coast

Join QuartzBio at the 8th Annual Bioinformatics Strategy Meeting East Coast USA for the “Omics-Driven Approaches” track on 23 May 2022.

ROUNDTABLE DISCUSSION: "Turning Multi-omic Data Chaos into Translational Insights"

Mike Waters of QuartzBio will facilitate a discussion among 10-15 industry leaders around critical topics relevant to biomarker-rich clinical trials:

Read More →
Breadth Depth Use case BDM image 20220118

From IHC to Immune Profiling: Managing Data Breadth and Depth to Inform On-Study Decisions

January 10, 2022 — With immuno-oncology assets progressing in the clinic, a growing biotechnology company we work with faces an increasingly common challenge:

Their trials are generating large datasets across a wide range of assay modalities (Figure 1), but the data remains siloed.

In addition to clinical data coming from the clinical research organization (CRO), the velocity of data coming from an assay services laboratory continuously delivering biomarker data from flow cytometry, immunohistochemistry, and genomics platforms quickly becomes overwhelming. Still another, separate data stream comes from a specialty laboratory delivering T-cell receptor (TCR) profiling data.

Read More →